文献速递心力衰竭与心肌病

恩格列净用于心力衰竭伴射血分数降低及容量负荷过重的患者:EMPEROR-Reduced试验

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本研究基于EMPEROR-Reduced试验,纳入3730例射血分数降低的心力衰竭患者,约40%在入组前4周内有容量负荷过重。结果显示,恩格列净较安慰剂降低心血管死亡或心衰住院复合风险、减少心衰总住院并改善健康状况和功能分级,但近期容量负荷过重患者亚组的获益幅度并未更显著(交互P>0.05),体重、红细胞压积和利钠肽的变化时间进程不平行,不支持利尿作用主导其临床获益。

要点

  • 恩格列净降低HFrEF患者心血管死亡或心衰住院复合风险,减少心衰总住院,改善健康状况和功能分级。
  • 近期容量负荷过重患者获益幅度未更显著(交互P>0.05),即使治疗1个月后亦如此。
  • 体重、红细胞压积和利钠肽变化不平行,不支持利尿作用主导恩格列净的生理改变或临床获益。

核心结论

  • 研究结果不支持利尿作用在介导SGLT2抑制剂对HFrEF患者心衰病程的生理改变或临床获益中占主导地位。

研究设计与样本

  • 双盲随机对照试验EMPEROR-Reduced,纳入3730例伴或不伴糖尿病的心力衰竭且射血分数降低的患者,比较恩格列净与安慰剂。
  • 约40%的患者在研究入组前4周内有容量负荷过重。

主要发现

  • 近期容量负荷过重患者更可能曾因心衰住院、过去12个月内在门诊接受静脉利尿剂、随机化后发生心衰事件,尽管更可能在门诊使用高剂量袢利尿剂(所有P<0.001)。
  • 与安慰剂相比,恩格列净降低心血管死亡或心衰住院复合风险、减少心衰总住院、改善健康状况和功能分级。
  • 近期容量负荷过重患者中上述获益幅度并未更显著(交互P>0.05),即使治疗1个月后亦如此。
  • 体重、红细胞压积和利钠肽的变化在时间进程或个体患者中并不密切平行。

临床怎么用

  • 恩格列净可用于HFrEF患者以降低心血管死亡或心衰住院复合风险、减少心衰总住院并改善健康状况和功能分级。
  • 不应仅因患者近期无容量负荷过重而限制恩格列净的使用,也不应期望容量负荷过重患者获得更大获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2) inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure events, and this action is particularly important in patients with fluid retention. OBJECTIVES: This study sought to evaluate the effects of the SGLT2 inhibitor empagliflozin on symptoms, health status, and major heart failure outcomes in patients with and without recent volume overload. METHODS: This double-blind randomized trial compared the effects of empagliflozin and placebo in 3,730 patients with heart failure and a reduced ejection fraction, with or without diabetes. Approximately 40% of the patients had volume overload in the 4 weeks before study enrollment. RESULTS: Patients with recent volume overload were more likely to have been hospitalized for heart failure and to have received an intravenous diuretic agent in an outpatient setting in the previous 12 months, and to experience a heart failure event following randomization, even though they were more likely to be treated with high doses of a loop diuretic agent as an outpatient (all p < 0.001). When compared with placebo, empagliflozin reduced the composite risk of cardiovascular death or hospitalization for heart failure, decreased total hospitalizations for heart failure, and improved health status and functional class. Yet despite the predisposition of patients with recent volume overload to fluid retention, the magnitude of these benefits (even after 1 month of treatment) was not more marked in patients with recent volume overload (interaction p values > 0.05). Changes in body weight, hematocrit, and natriuretic peptides (each potentially indicative of a diuretic action of SGLT2 inhibitors) did not track each other closely in their time course or in individual patients. CONCLUSIONS: Taken together, study findings do not support a dominant role of diuresis in mediating the physiological changes or clinical benefits of SGLT2 inhibitors on the course of heart failure in patients with a reduced ejection fraction. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Packer M, Anker SD, Butler J, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021. PMID: 33736819. doi:10.1016/j.jacc.2021.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。